Phio Pharmaceuticals (PHIO) said Thursday its safety monitoring committee has approved progressing to a higher dose level in its phase 1b trial of PH-762, an investigational therapy for advanced skin cancers, following positive safety data from the second dose group.
The company said the trial evaluates the safety and tolerability of PH-762, delivered through intratumoral injections, in stages 1, 2, and 4 cutaneous squamous cell carcinoma, stage 4 melanoma and stage 4 Merkel cell carcinoma.
In the second dose group, which comprises four patients with cutaneous squamous cell carcinoma, two patients showed tumor reductions, with one achieving complete clearance, Phio said. Data from the remaining two patients is pending, the company added.
The company's shares were up more than 27% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。